214 related articles for article (PubMed ID: 22235146)
21. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.
Rumpold H; Salvador C; Wolf AM; Tilg H; Gastl G; Wolf D
Biochem Biophys Res Commun; 2007 Sep; 361(2):549-54. PubMed ID: 17662692
[TBL] [Abstract][Full Text] [Related]
22. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
23. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
Dick LR; Fleming PE
Drug Discov Today; 2010 Mar; 15(5-6):243-9. PubMed ID: 20116451
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.
Janneh O; Anwar T; Jungbauer C; Kopp S; Khoo SH; Back DJ; Chiba P
Antivir Ther; 2009; 14(7):965-74. PubMed ID: 19918100
[TBL] [Abstract][Full Text] [Related]
25. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
[TBL] [Abstract][Full Text] [Related]
26. Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells.
Weerasinghe P; Hallock S; Tang SC; Trump B; Liepins A
Exp Toxicol Pathol; 2006 Aug; 58(1):21-30. PubMed ID: 16735106
[TBL] [Abstract][Full Text] [Related]
27. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
28. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
Yang Y; Gao Y; Huang J; Yang Z; Luo H; Wang F; Xu J; Cui Y; Ding H; Lin Z; Zhai X; Qu Y; Zhang L; Liu T; Ye L; Niu T; Zheng Y
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36040812
[TBL] [Abstract][Full Text] [Related]
29. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Arastu-Kapur S; Anderl JL; Kraus M; Parlati F; Shenk KD; Lee SJ; Muchamuel T; Bennett MK; Driessen C; Ball AJ; Kirk CJ
Clin Cancer Res; 2011 May; 17(9):2734-43. PubMed ID: 21364033
[TBL] [Abstract][Full Text] [Related]
30. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
31. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
[TBL] [Abstract][Full Text] [Related]
32. The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
Lü S; Chen Z; Yang J; Chen L; Zhou H; Xu X; Li J; Han F; Wang J
Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e123-31. PubMed ID: 19254348
[TBL] [Abstract][Full Text] [Related]
33. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Orlowski RZ
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
35. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
36. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
37. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of protein expression profiles between bortezomib-resistant JurkatB cells with PSMB5 mutation and their parent cells].
Lü SQ; Yang JM; Huang CM; Xu XQ; Zhou H; Song NX; Wang JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):869-73. PubMed ID: 21867604
[TBL] [Abstract][Full Text] [Related]
39. Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide).
Johnson HWB; Lowe E; Anderl JL; Fan A; Muchamuel T; Bowers S; Moebius DC; Kirk C; McMinn DL
J Med Chem; 2018 Dec; 61(24):11127-11143. PubMed ID: 30380863
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib (Kryprolis) for multiple myeloma.
Med Lett Drugs Ther; 2012 Dec; 54(1406):103-4. PubMed ID: 23282792
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
